Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
Ejhaem
|
October 6, 2025
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience
Dipal Mehta, Maria Gabriel, Nathan Adu-Poku, et al.
Haematologica
|
August 25, 2022
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
Samir Asher, Aikaterini Kazantzi, Fatjon Dekaj, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 3, 2022
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study
Marquita Camilleri, Georgios Bekris, Govundeep Sidhu, et al.
British Journal of Haematology
|
August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
British Journal of Cancer
|
May 22, 2020
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design
Dimitrios A Koutoukidis, Joanne Land, Allan Hackshaw, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
July 2, 2024
The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study
Caroline Buck, Francisco Brenes Castillo, Elena Bettio, et al.
British Journal of Haematology
|
July 29, 2021
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
Wei Yee Chan, Emilie Sanchez, Selina J Chavda, et al.
British Journal of Haematology
|
November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse
Oliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma
|
May 16, 2022
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination
Lara Howells, Wei Yee Chan, Emilie Sanchez, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
Ejhaem
|
October 6, 2025
The Role of Radiotherapy for Patients With Multiple Myeloma in the Modern Era: A Real World Single-Centre Experience
Dipal Mehta, Maria Gabriel, Nathan Adu-Poku, et al.
Haematologica
|
August 25, 2022
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
Samir Asher, Aikaterini Kazantzi, Fatjon Dekaj, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 3, 2022
The impact of COVID-19 on autologous stem cell transplantation in multiple myeloma: A single-centre, qualitative evaluation study
Marquita Camilleri, Georgios Bekris, Govundeep Sidhu, et al.
British Journal of Haematology
|
August 8, 2019
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy
Richa Manwani, Shameem Mahmood, Sajitha Sachchithanantham, et al.
British Journal of Cancer
|
May 22, 2020
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design
Dimitrios A Koutoukidis, Joanne Land, Allan Hackshaw, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
July 2, 2024
The impact of continuous lenalidomide maintenance treatment on people living with multiple myeloma-a single-centre, qualitative service evaluation study
Caroline Buck, Francisco Brenes Castillo, Elena Bettio, et al.
British Journal of Haematology
|
July 29, 2021
Development of antibody response to SARS-CoV-2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
Wei Yee Chan, Emilie Sanchez, Selina J Chavda, et al.
British Journal of Haematology
|
November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse
Oliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
Leukemia & Lymphoma
|
May 16, 2022
Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination
Lara Howells, Wei Yee Chan, Emilie Sanchez, et al.
Page
of 8